Filtern
Volltext vorhanden
- ja (11)
Gehört zur Bibliographie
- ja (11)
Dokumenttyp
Sprache
- Englisch (11)
Schlagworte
- regulatory T cells (3)
- CD4(+) (2)
- T cells (2)
- cytokine secretion (2)
- B cells (1)
- CD28 (1)
- CD28 costimulation (1)
- CD28 superagonists (1)
- CD4(+)CD25(+) (1)
- CD4\(^{+}\) T cells (1)
- CD4\(^{+}\) T helper cells (1)
- Candida albicans (1)
- D665 (1)
- Graft versus Tumor (1)
- Hsp90 (1)
- Medizin (1)
- Parkinson’s disease (1)
- T helper 1 cells (1)
- TAB08 (1)
- TGF-BETA (1)
- TGN1412 (1)
- acute Graft versus Host Disease (1)
- acute graft-versus-host disease (1)
- adoptive transfer (1)
- antibodies (1)
- antigen presentation (1)
- antigenic recall (1)
- autoimmunity (1)
- brain (1)
- central-nervous-system (1)
- co-stimulation, (1)
- enzyme-linked immunoassays (1)
- gamma-interferon (1)
- heart (1)
- heart failure (1)
- human (1)
- immune evasion (1)
- improves survival (1)
- in-vivo (1)
- inducible deletion (1)
- infected mice (1)
- kidneys (1)
- leukemia (1)
- measles virus (1)
- mediated suppression (1)
- memory B cells (1)
- mice (1)
- mouse (1)
- neuroinflammation (1)
- neuroprotection (1)
- pH-regulated antigen 1 (Pra1) (1)
- polymicrobial sepsis (1)
- retroviral infection (1)
- self-reactivity (1)
- subacute sclerosing-panencephalitis (1)
- toll-like receptors (1)
- virus-induced encephalitis (1)
Institut
EU-Projektnummer / Contract (GA) number
- 825575 (1)
Background
Regulatory CD4\(^+\)CD25\(^+\)FoxP3\(^+\) T cells (Treg) are a subgroup of T lymphocytes involved in maintaining immune balance. Disturbance of Treg number and impaired suppressive function of Treg correlate with Parkinson’s disease severity. Superagonistic anti-CD28 monoclonal antibodies (CD28SA) activate Treg and cause their expansion to create an anti-inflammatory environment.
Methods
Using the AAV1/2-A53T-α-synuclein Parkinson’s disease mouse model that overexpresses the pathogenic human A53T-α-synuclein (hαSyn) variant in dopaminergic neurons of the substantia nigra, we assessed the neuroprotective and disease-modifying efficacy of a single intraperitoneal dose of CD28SA given at an early disease stage.
Results
CD28SA led to Treg expansion 3 days after delivery in hαSyn Parkinson’s disease mice. At this timepoint, an early pro-inflammation was observed in vehicle-treated hαSyn Parkinson’s disease mice with elevated percentages of CD8\(^+\)CD69\(^+\) T cells in brain and increased levels of interleukin-2 (IL-2) in the cervical lymph nodes and spleen. These immune responses were suppressed in CD28SA-treated hαSyn Parkinson’s disease mice. Early treatment with CD28SA attenuated dopaminergic neurodegeneration in the SN of hαSyn Parkinson’s disease mice accompanied with reduced brain numbers of activated CD4\(^+\), CD8\(^+\) T cells and CD11b\(^+\) microglia observed at the late disease-stage 10 weeks after AAV injection. In contrast, a later treatment 4 weeks after AAV delivery failed to reduce dopaminergic neurodegeneration.
Conclusions
Our data indicate that immune modulation by Treg expansion at a timepoint of overt inflammation is effective for treatment of hαSyn Parkinson’s disease mice and suggest that the concept of early immune therapy could pose a disease-modifying option for Parkinson’s disease patients.